prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |review

Key Point: In the STELLAR trial, rosuvastatin established and maintained increased
HDL-C with every dose, while improvements in HDL-C decreased with increasing atorvastatin doses.

In 20-mg and 40-mg-dose comparisons, rosuvastatin therapy resulted in a statistically significant greater increase in HDL-C compared with atorvastatin 20, 40, and 80 mg (P<.002)

Rosuvastatin 10 mg raised HDL-C significantly more than pravastatin 10 mg (P<.002)

Rosuvastatin 20 mg raised HDL-C significantly more than atorvastatin 20, 40,
80 mg, simvastatin 40 mg, and pravastatin 20, 40 mg (
P<.002)

Rosuvastatin 40 mg raised HDL-C significantly more than atorvastatin 40,
80 mg, simvastatin 40 mg, and pravastatin 40 mg (
P<.002)












 

Reference

Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin
versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).
Am J Cardiol.
2003;93:152-160.